Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis-related diabetes.

Frost F, Jones GH, Dyce P, Jackson V, Nazareth D, Walshaw MJ.

Diabet Med. 2019 Nov;36(11):1367-1374. doi: 10.1111/dme.14121. Epub 2019 Sep 17.

PMID:
31466128
2.

Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data.

Frost FJ, Nazareth DS, Charman SC, Winstanley C, Walshaw MJ.

Ann Am Thorac Soc. 2019 Nov;16(11):1375-1382. doi: 10.1513/AnnalsATS.201902-122OC.

PMID:
31319678
3.

Cystic fibrosis-related diabetes: optimizing care with a multidisciplinary approach.

Frost F, Dyce P, Ochota A, Pandya S, Clarke T, Walshaw MJ, Nazareth DS.

Diabetes Metab Syndr Obes. 2019 Apr 26;12:545-552. doi: 10.2147/DMSO.S180597. eCollection 2019.

4.

Cystic fibrosis: Diagnosis and management - NICE guideline 78.

Walshaw MJ.

Paediatr Respir Rev. 2019 Aug;31:12-14. doi: 10.1016/j.prrv.2019.02.006. Epub 2019 Feb 28. Review.

PMID:
30962150
5.

Cystic fibrosis related diabetes is not independently associated with increased Stenotrophomonas maltophilia infection: Longitudinal data from the UK CF Registry.

Frost F, Nazareth D, Shaw M, Walshaw MJ.

J Cyst Fibros. 2019 Mar;18(2):294-298. doi: 10.1016/j.jcf.2018.10.011. Epub 2018 Oct 25.

PMID:
30741162
6.

Between a Rock and an Airspace: Pneumothorax After Extracorporeal Shock Wave Lithotripsy for Renal Stones in a Patient With Cystic Fibrosis.

Frost F, Griffiths P, Brockelsby C, Lynch C, Walshaw MJ, Nazareth D.

Chest. 2018 Sep;154(3):e61-e63. doi: 10.1016/j.chest.2018.03.023.

PMID:
30195371
7.

Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes.

Frost F, Dyce P, Nazareth D, Malone V, Walshaw MJ.

J Cyst Fibros. 2018 Nov;17(6):798-803. doi: 10.1016/j.jcf.2018.05.005. Epub 2018 Jun 7.

PMID:
29885744
8.

Transmission and lineage displacement drive rapid population genomic flux in cystic fibrosis airway infections of a Pseudomonas aeruginosa epidemic strain.

Williams D, Fothergill JL, Evans B, Caples J, Haldenby S, Walshaw MJ, Brockhurst MA, Winstanley C, Paterson S.

Microb Genom. 2018 Mar;4(3). doi: 10.1099/mgen.0.000167. Epub 2018 Mar 16.

9.

Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung.

Hilliam Y, Moore MP, Lamont IL, Bilton D, Haworth CS, Foweraker J, Walshaw MJ, Williams D, Fothergill JL, De Soyza A, Winstanley C.

Eur Respir J. 2017 Apr 26;49(4). pii: 1602108. doi: 10.1183/13993003.02108-2016. Print 2017 Apr.

10.

Potential impact on fertility of new systemic therapies for cystic fibrosis.

Jones GH, Walshaw MJ.

Paediatr Respir Rev. 2015 Oct;16 Suppl 1:25-7. doi: 10.1016/j.prrv.2015.07.013. Epub 2015 Sep 26. Review.

PMID:
26410278
11.

Divergent, coexisting Pseudomonas aeruginosa lineages in chronic cystic fibrosis lung infections.

Williams D, Evans B, Haldenby S, Walshaw MJ, Brockhurst MA, Winstanley C, Paterson S.

Am J Respir Crit Care Med. 2015 Apr 1;191(7):775-85. doi: 10.1164/rccm.201409-1646OC.

12.

Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections.

James CE, Davies EV, Fothergill JL, Walshaw MJ, Beale CM, Brockhurst MA, Winstanley C.

ISME J. 2015 Jun;9(6):1391-8. doi: 10.1038/ismej.2014.223. Epub 2014 Dec 2.

13.

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients.

Fothergill JL, Ledson MJ, Walshaw MJ, McNamara PS, Southern KW, Winstanley C.

J Cyst Fibros. 2013 Dec;12(6):675-81. doi: 10.1016/j.jcf.2013.04.007. Epub 2013 May 29.

14.

Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis.

Ashish A, Paterson S, Mowat E, Fothergill JL, Walshaw MJ, Winstanley C.

J Cyst Fibros. 2013 Dec;12(6):790-3. doi: 10.1016/j.jcf.2013.04.003. Epub 2013 May 1.

15.

Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study.

Ashish A, Shaw M, Winstanley C, Humphreys L, Walshaw MJ.

JRSM Short Rep. 2013 Jan;4(1):1. doi: 10.1258/shorts.2012.012018. Epub 2013 Jan 14.

16.

Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice.

Bolton CE, Bush A, Hurst JR, Kotecha S, McGarvey L, Stocks J, Walshaw MJ.

Thorax. 2012 Dec;67(12):1110. doi: 10.1136/thoraxjnl-2012-202637. Epub 2012 Sep 19.

PMID:
22993167
17.

Health-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study.

Ashish A, Shaw M, McShane J, Ledson MJ, Walshaw MJ.

JRSM Short Rep. 2012 Feb;3(2):12. doi: 10.1258/shorts.2011.011119. Epub 2012 Feb 27.

18.

Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections.

Fothergill JL, Walshaw MJ, Winstanley C.

Eur Respir J. 2012 Jul;40(1):227-38. doi: 10.1183/09031936.00204411. Epub 2012 Feb 9.

19.

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)--a cause for concern?

Ashish A, Shaw M, Winstanley C, Ledson MJ, Walshaw MJ.

J Cyst Fibros. 2012 May;11(3):173-9. doi: 10.1016/j.jcf.2011.11.004. Epub 2011 Dec 5.

20.

Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections.

Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, Brockhurst MA, Winstanley C.

Am J Respir Crit Care Med. 2011 Jun 15;183(12):1674-9. doi: 10.1164/rccm.201009-1430OC. Epub 2011 Feb 4.

PMID:
21297072
21.

Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Fothergill JL, Mowat E, Walshaw MJ, Ledson MJ, James CE, Winstanley C.

Antimicrob Agents Chemother. 2011 Jan;55(1):426-8. doi: 10.1128/AAC.01257-10. Epub 2010 Oct 25.

22.

A subtype of a Pseudomonas aeruginosa cystic fibrosis epidemic strain exhibits enhanced virulence in a murine model of acute respiratory infection.

Carter ME, Fothergill JL, Walshaw MJ, Rajakumar K, Kadioglu A, Winstanley C.

J Infect Dis. 2010 Sep 15;202(6):935-42. doi: 10.1086/655781.

PMID:
20704484
23.

Impact of Pseudomonas aeruginosa genomic instability on the application of typing methods for chronic cystic fibrosis infections.

Fothergill JL, White J, Foweraker JE, Walshaw MJ, Ledson MJ, Mahenthiralingam E, Winstanley C.

J Clin Microbiol. 2010 Jun;48(6):2053-9. doi: 10.1128/JCM.00019-10. Epub 2010 Apr 21.

24.

Empyema due to a highly transmissible Pseudomonas aeruginosa strain in an adult cystic fibrosis patient.

Mohan K, Lakshman V, Fothergill JL, Ledson MJ, Winstanley C, Walshaw MJ.

J Med Microbiol. 2010 May;59(Pt 5):614-6. doi: 10.1099/jmm.0.014696-0. Epub 2010 Feb 4.

PMID:
20133415
25.

Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations.

Fothergill JL, Mowat E, Ledson MJ, Walshaw MJ, Winstanley C.

J Med Microbiol. 2010 Apr;59(Pt 4):472-81. doi: 10.1099/jmm.0.015875-0. Epub 2009 Dec 17.

PMID:
20019149
26.

Simultaneous bilateral spontaneous pneumothorax in an adult patient with cystic fibrosis.

Mohan K, Ledson MJ, Walshaw MJ, Marchiori E.

J Bras Pneumol. 2009 Feb;35(2):194-6.

27.

The role of specialist lung cancer nurses in the UK: a national survey.

Brown L, McPhelim J, Devereux G, Mohan K, Walshaw MJ.

Thorax. 2009 Feb;64(2):181-2. doi: 10.1136/thx.2008.106625. No abstract available.

PMID:
19176846
28.

Transmission of Pseudomonas aeruginosa epidemic strain from a patient with cystic fibrosis to a pet cat.

Mohan K, Fothergill JL, Storrar J, Ledson MJ, Winstanley C, Walshaw MJ.

Thorax. 2008 Sep;63(9):839-40. doi: 10.1136/thx.2007.092486.

PMID:
18728207
29.

Management of cystic fibrosis related diabetes: a survey of UK cystic fibrosis centers.

Mohan K, Miller H, Burhan H, Ledson MJ, Walshaw MJ.

Pediatr Pulmonol. 2008 Jul;43(7):642-7. doi: 10.1002/ppul.20831.

PMID:
18500737
30.

Long-term effect of insulin treatment in cystic fibrosis-related diabetes.

Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ.

Respiration. 2008;76(2):181-6. Epub 2007 Oct 25.

PMID:
17960051
31.

Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain.

Fothergill JL, Panagea S, Hart CA, Walshaw MJ, Pitt TL, Winstanley C.

BMC Microbiol. 2007 May 23;7:45.

32.

Does breastfeeding method influence infant weight gain?

Walshaw CA, Owens JM, Scally AJ, Walshaw MJ.

Arch Dis Child. 2008 Apr;93(4):292-6. Epub 2007 Feb 14.

PMID:
17301107
33.

Development of a diagnostic test for the Midlands 1 cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Smart CH, Scott FW, Wright EA, Walshaw MJ, Hart CA, Pitt TL, Winstanley C.

J Med Microbiol. 2006 Aug;55(Pt 8):1085-91.

PMID:
16849729
34.
35.

A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance.

Salunkhe P, Smart CH, Morgan JA, Panagea S, Walshaw MJ, Hart CA, Geffers R, T├╝mmler B, Winstanley C.

J Bacteriol. 2005 Jul;187(14):4908-20.

36.

Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES).

Al-Aloul M, Miller H, Stockton P, Ledson MJ, Walshaw MJ.

J Cyst Fibros. 2005 Sep;4(3):197-201.

37.

Burkholderia infection and survival in CF.

Ledson MJ, Walshaw MJ.

Thorax. 2005 May;60(5):439. No abstract available.

38.
39.

Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.

Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ.

Pediatr Pulmonol. 2005 Jan;39(1):15-20.

PMID:
15521084
40.

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.

Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ.

J Cyst Fibros. 2003 Mar;2(1):19-24.

41.

PCR-based detection of a cystic fibrosis epidemic strain of Pseudomonas Aeruginosa.

Panagea S, Winstanley C, Parsons YN, Walshaw MJ, Ledson MJ, Hart CA.

Mol Diagn. 2003;7(3-4):195-200.

PMID:
15068391
42.

Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients.

Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ.

Thorax. 2004 Apr;59(4):334-6.

43.

Bronchoscopic insertion of Gianturco stents for the palliation of malignant lung disease: 10 year experience.

Stockton PA, Ledson MJ, Hind CR, Walshaw MJ.

Lung Cancer. 2003 Oct;42(1):113-7.

PMID:
14512195
44.

Posture and cystic fibrosis.

Tattersall R, Walshaw MJ.

J R Soc Med. 2003;96 Suppl 43:18-22. Review. No abstract available.

45.

Autonomic dysfunction in cystic fibrosis.

Mirakhur A, Walshaw MJ.

J R Soc Med. 2003;96 Suppl 43:11-7. Review. No abstract available.

47.

Intratracheal cocaine induced myocardial infarction: an unusual complication of fibreoptic bronchoscopy.

Osula S, Stockton P, Abdelaziz MM, Walshaw MJ.

Thorax. 2003 Aug;58(8):733-4.

48.

Use of subtractive hybridization to identify a diagnostic probe for a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Parsons YN, Panagea S, Smart CH, Walshaw MJ, Hart CA, Winstanley C.

J Clin Microbiol. 2002 Dec;40(12):4607-11.

49.

Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives.

McCallum SJ, Gallagher MJ, Corkill JE, Hart CA, Ledson MJ, Walshaw MJ.

Thorax. 2002 Jun;57(6):559-60.

50.

A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia.

Ledson MJ, Gallagher MJ, Robinson M, Cowperthwaite C, Williets T, Hart CA, Walshaw MJ.

J Aerosol Med. 2002 Spring;15(1):51-7.

PMID:
12006145

Supplemental Content

Loading ...
Support Center